FDA approved Plozasiran (now REDEMPLO™) on November 18, 2025, for reducing triglycerides in adults with FCS, the first siRNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback